ACLARION, INC(ACON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACON ACLARION, INC

Market Closed 05-22 16:00:00 EDT

3.21

-0.05

-1.53%

盘后3.21

+0.000.00%

17:06 EDT

High3.31	Low3.17	Vol25.07K
Open3.19	D1 Closing3.26	Amplitude4.27%
Mkt Cap7.90M	Tradable Cap7.12M	Total Shares2.46M
T/O81.41K	T/O Rate1.13%	Tradable Shares2.22M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACON","market":"US","secType":"STK","nameCN":"ACLARION, INC","latestPrice":3.21,"timestamp":1779480000000,"preClose":3.26,"halted":0,"volume":25073,"hourTrading":{"tag":"盘后","latestPrice":3.21,"preClose":3.21,"latestTime":"17:06 EDT","volume":63,"amount":200.76,"timestamp":1779483997566,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.015337423312883382,"floatShares":2218200,"shares":2462300,"eps":-9.5572,"marketStatus":"Market Closed","change":-0.05,"latestTime":"05-22 16:00:00 EDT","open":3.19,"high":3.3093,"low":3.17,"amount":81408.0845098,"amplitude":0.04273,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.5572,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"listingDate":1650600000000,"exchange":"NASDAQ","adjPreClose":3.26,"preHourTrading":{"tag":"盘前","latestPrice":3.3,"preClose":3.26,"latestTime":"06:49 EDT","volume":1,"amount":3.3,"timestamp":1779446954416,"change":0.04,"changeRate":0.01227,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":3.21,"preClose":3.21,"latestTime":"17:06 EDT","volume":63,"amount":200.76,"timestamp":1779483997566,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.290307645366081},"requestUrl":"/m/hq/s/ACON/wiki","defaultTab":"wiki","newsList":[{"id":"2635675185","title":"Aclarion Q1 EPS $(1.34) Beats $(1.55) Estimate, Sales $21.140K Miss $25.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635675185","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635675185?lang=en_us&edition=fundamental","pubTime":"2026-05-14 05:50","pubTimestamp":1778709025,"startTime":"0","endTime":"0","summary":"Aclarion (NASDAQ:ACON) reported quarterly losses of $(1.34) per share which beat the analyst consensus estimate of $(1.55) by 13.55 percent. This is a 85.62 percent increase over losses of $(9.32) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52547856/aclarion-q1-eps-1-34-beats-1-55-estimate-sales-21-140k-miss-25-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aclarion Q1 EPS $(1.34) Beats $(1.55) Estimate, Sales $21.140K Miss $25.000K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","ACON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635975530","title":"Aclarion Q1 FY26 net loss widens to $2.85 million; revenue rises 11.3% to $21,140","url":"https://stock-news.laohu8.com/highlight/detail?id=2635975530","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635975530?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:32","pubTimestamp":1778704337,"startTime":"0","endTime":"0","summary":"Aclarion posted a net loss of USD 2.85 million for quarter ended March 31, 2026, widening from USD 2.04 million a year earlier.Revenue rose 11.3% to USD 21,140, while gross profit swung to USD 3,750 from a gross loss of USD 4,488.Operating loss widened to USD 2.99 million from USD 1.49 million as operating expenses more than doubled to USD 2.99 million.Sales and marketing costs jumped to USD 908,797 from USD 302,584, while general and administrative expense climbed to USD 1.77 million from USD 986,663.Cash and cash equivalents totaled USD 19.03 million at March 31, 2026 following a registered direct public offering that raised about USD 10.4 million in gross proceeds.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. publish","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL7th7yZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","ACON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635784226","title":"Aclarion director Scott Breidbart acquires 5,664 shares worth $18,012.48","url":"https://stock-news.laohu8.com/highlight/detail?id=2635784226","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635784226?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:54","pubTimestamp":1778626446,"startTime":"0","endTime":"0","summary":"Aclarion director Scott Breidbart bought 5,664 shares of common stock in an open-market purchase.Shares were acquired at USD 3.18 each, leaving him with 5,664 shares held directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL2ZCn05:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634211829","title":"Aclarion director David K. Neal acquires 2,500 common shares worth $7,750","url":"https://stock-news.laohu8.com/highlight/detail?id=2634211829","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634211829?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:31","pubTimestamp":1778589068,"startTime":"0","endTime":"0","summary":"Aclarion director David K. Neal disclosed a purchase of 2,500 common shares at USD 3.1 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL3bZJYx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Aclarion director David K. Neal acquires 2,500 common shares worth $7,750","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","ACON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634246732","title":"Aclarion director William Wesemann acquires 1,562 common shares for $5,154.6","url":"https://stock-news.laohu8.com/highlight/detail?id=2634246732","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634246732?lang=en_us&edition=fundamental","pubTime":"2026-05-09 05:01","pubTimestamp":1778274094,"startTime":"0","endTime":"0","summary":"Aclarion director William Wesemann disclosed an open-market purchase of 1,562 common shares at USD 3.3 each.Stake rose to 1,563 common shares held directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL34ts5K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aclarion director William Wesemann acquires 1,562 common shares for $5,154.6","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","ACON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633946117","title":"Aclarion Inc - Expects Public Disclosure of Early Interim Clarity Trial Results in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633946117","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633946117?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:00","pubTimestamp":1778148000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUA19L0HQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","ACON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633343112","title":"Aclarion Announces Addition of First Private Practice Site in Los Angeles Into Clarity Trial to Further Accelerate Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2633343112","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633343112?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:00","pubTimestamp":1778148000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUA19L0HQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","ACON","ACONW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633394186","title":"Aclarion grants new Western US commercial director option for 17,000 shares at $3.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2633394186","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633394186?lang=en_us&edition=fundamental","pubTime":"2026-05-06 18:04","pubTimestamp":1778061859,"startTime":"0","endTime":"0","summary":"Aclarion granted newly hired Commercial Director, Western U.S. Daniel Keefe an inducement stock option to buy 17,000 common shares on May 5, 2026.Exercise price set at USD 3.2 per share, matching closing price on grant date.Vesting set at 25% on one-year anniversary of vesting commencement date, remainder in equal monthly installments over next three years; option term set at 10 years.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL9c2Rvy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4112","LU2095319765.USD","IE00BGHQF748.EUR","ACON","IE00BN0W2W23.USD","NDAQ","LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014021.USD","LU2210149790.SGD","SG9999014013.SGD","SG9999014005.SGD","IE00BN0W2V16.EUR","SG9999014039.USD","BK4588","IE00BKPKM429.USD","BK4167","LU0314104364.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633185137","title":"Press Release: Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2633185137","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633185137?lang=en_us&edition=fundamental","pubTime":"2026-05-06 18:00","pubTimestamp":1778061600,"startTime":"0","endTime":"0","summary":"BROOMFIELD, Colo., May 06, 2026  -- Aclarion, Inc.,  , a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence  algorithms through its Nociscan platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today announced that the compensation committee of Aclarion's board of directors granted Daniel Keefe, the Company's recently-hired Commercial Director, Western U.S., an inducement stock option to purchase an aggregate of 17,000 shares of Aclarion's common stock on May 5, 2026. This stock option was agreed to as an inducement material to Mr. Keefe entering into employment with Aclarion. The option was agreed to and granted in accordance with Nasdaq Listing Rule 5635.This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4022","ACON","BK4232","BK4168","BK4167","WRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633916522","title":"BRIEF-Aclarion Announces Second Commercial Agreement With Weill Cornell Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2633916522","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633916522?lang=en_us&edition=fundamental","pubTime":"2026-05-05 18:08","pubTimestamp":1777975680,"startTime":"0","endTime":"0","summary":"BRIEF-Aclarion Announces Second Commercial Agreement With Weill Cornell MedicineMay 5 (Reuters) - Aclarion Inc ACON.O:ACLARION ANNOUNCES SECOND COMMERCIAL AGREEMENT WITH WEILL CORNELL MEDICINESource text: ID:nGNX9dDQ6ZFurther company coverage: ACON.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nTUABXNRL8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON","ACONW","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633379916","title":"Aclarion signs second commercial agreement with Weill Cornell Medicine for Nociscan trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2633379916","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633379916?lang=en_us&edition=fundamental","pubTime":"2026-05-05 18:05","pubTimestamp":1777975500,"startTime":"0","endTime":"0","summary":"Aclarion signed a second commercial agreement with Weill Cornell Medicine to bring Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center via a clinical trial.Nociscan will be used in a prospective randomized controlled trial evaluating lumbar microdiscectomy with or without intradiscal bone marrow aspirate concentrate injection, tracking outcomes, disc health, and pain biomarkers over two years.Study is led by neurosurgeon Roger Hrtl under IRB Protocol No. 24-09027977.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL1Y4TG3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4112","LU2210150020.SGD","NDAQ","SG9999014005.SGD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","ACON","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014039.USD","BK4585","SG9999014021.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BN0W2V16.EUR","LU0314104364.USD","BK4588","BK4167","IE00BGHQF748.EUR","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631687986","title":"Aclarion announces $2.5 million share buyback program","url":"https://stock-news.laohu8.com/highlight/detail?id=2631687986","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631687986?lang=en_us&edition=fundamental","pubTime":"2026-04-30 18:10","pubTimestamp":1777543837,"startTime":"0","endTime":"0","summary":"Aclarion launched a $2.5 million share repurchase program.Company projected cash runway into second half of 2027, factoring in impact of the buyback.Cash totaled $19 million as of March 31, 2026, with no debt.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief on April 30, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDLbVvrGW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630372241","title":"Aclarion appoints Daniel Keefe commercial director for Western US","url":"https://stock-news.laohu8.com/highlight/detail?id=2630372241","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630372241?lang=en_us&edition=fundamental","pubTime":"2026-04-28 18:04","pubTimestamp":1777370656,"startTime":"0","endTime":"0","summary":"Aclarion appointed Daniel Keefe as Commercial Director, Western U.S., to lead regional commercialization and accelerate adoption of Nociscan.Role expands commercial coverage as Nociscan utilization posts triple-digit growth.Keefe brings more than 20 years of medical device and healthcare technology sales experience, most recently serving as Regional Sales Manager at Centinel Spine.Prior roles included positions at Brainlab, Zimmer Biomet, Intuitive Surgical.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL3tRW4d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z8X17.USD","LU2095319765.USD","ISUL","LU1267930813.SGD","LU2433249047.HKD","LU0006061336.USD","IE00B19Z8W00.USD","LU1923622614.USD","LU0211328371.USD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU0310800379.SGD","LU0058720904.USD","LU1983299246.USD","LU0477156953.USD","LU1868837300.USD","LU2023250504.SGD","BK4585","BK4588","LU0390134368.USD","LU1974910355.USD","LU1989764664.SGD","LU0128525929.USD","IE00BFXG0V08.USD","LU0882574055.USD","LU2210150020.SGD","LU0079474960.USD","BK4548","LU1023059063.AUD","ACON","IE00BGHQF748.EUR","BK4504","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2324357040.USD","LU0061475181.USD","BK4112","LU0823434740.USD","IE00B5TLWC47.USD","IE00B7SZLL34.SGD","LU1951198990.SGD","LU2112291526.USD","LU0310799852.SGD","LU0314104364.USD","SG9999014039.USD","ZBH","NDAQ","IE00B64PRP62.GBP","LU0823434583.USD","ISRG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630737783","title":"Press Release: Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan","url":"https://stock-news.laohu8.com/highlight/detail?id=2630737783","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630737783?lang=en_us&edition=fundamental","pubTime":"2026-04-28 18:00","pubTimestamp":1777370400,"startTime":"0","endTime":"0","summary":"-- Commercial leader with proven track record of driving growth, surgeon. adoption, and market expansion with innovative spine and surgical. -- Expansion of commercial team reflects increasing demand for Nociscan,Dan will lead commercial efforts across the Western region, building on Aclarion's existing footprint and supporting continued adoption of Nociscan. Aclarion has established a growing presence across the Western U.S., with engagement spanning both academic institutions and high-volume private practice spine centers, supported by strong volume growth. Dan's appointment reflects the Company's focus on expanding this momentum and deepening adoption in a key strategic region.\"I'm excited to join Aclarion at a time when Nociscan is gaining meaningful traction across the clinical community,\" said Daniel Keefe, Commercial Director, Western U.S., Aclarion. \"The ability to provide physicians with objective insight into the source of pain represents a significant advancement in how chro","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WRN","BK4167","ACON","BK4168"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629044419","title":"Aclarion announces $2.5M share repurchase program","url":"https://stock-news.laohu8.com/highlight/detail?id=2629044419","media":"TIPRANKS","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629044419?lang=en_us&edition=fundamental","pubTime":"2026-04-22 21:10","pubTimestamp":1776863435,"startTime":"0","endTime":"0","summary":"Aclarion (ACON) announced that its board of directors has authorized a share repurchase program of up to $2.5M of the company’s outstanding common ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclarion-announces-2-5m-share-repurchase-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclarion-announces-2-5m-share-repurchase-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACON","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629041252","title":"Aclarion Inc - Repurchase Program Expected to Be Executed Over Next 12 Months - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2629041252","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629041252?lang=en_us&edition=fundamental","pubTime":"2026-04-22 21:01","pubTimestamp":1776862905,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nFWN41515W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACON","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629495010","title":"Aclarion launches USD 2.5 million share buyback program","url":"https://stock-news.laohu8.com/highlight/detail?id=2629495010","media":"Reuters","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629495010?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:33","pubTimestamp":1776861183,"startTime":"0","endTime":"0","summary":"Aclarion authorized share repurchase program of up to USD 2.5 million for outstanding common stock.Company expects to execute buyback over next 12 months.Repurchases to be funded with existing cash and cash equivalents.Cash and cash equivalents totaled about USD 19 million as of March 31, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL48k32f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU2095319765.USD","SG9999014005.SGD","LU2210150020.SGD","ACON","BK4585","BK4112","NDAQ","SG9999014021.USD","BK4588","IE00BGHQF748.EUR","LU2210149790.SGD","LU0314104364.USD","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014039.USD","BK4167","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629049354","title":"Aclarion Announces $2.5 Million Stock Repurchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2629049354","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629049354?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:30","pubTimestamp":1776861000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUA9Q7SBL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","ACONW","ACON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627294556","title":"Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2627294556","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627294556?lang=en_us&edition=fundamental","pubTime":"2026-04-16 18:47","pubTimestamp":1776336479,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nFWN40Y17T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACON","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627512294","title":"Aclarion secures U.S. patent for AI-based chronic low back pain assessment platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2627512294","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627512294?lang=en_us&edition=fundamental","pubTime":"2026-04-16 18:47","pubTimestamp":1776336450,"startTime":"0","endTime":"0","summary":"Aclarion secured U.S. Patent 12,601,803 covering machine learning-based training and prediction to evaluate pain using magnetic resonance spectroscopy data.Patent supports planned automation in future Nociscan workflows, targeting faster report generation and fewer manual quality reviews.IP portfolio expanded to 64 issued and pending patents worldwide, strengthening competitive positioning in chronic low back pain assessment.Clinical data cited up to 97% surgical success rate when all Nociscan-positive discs are treated alongside other diagnostic tools.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL2BHTqK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014021.USD","BK4585","IE00BN0W2V16.EUR","LU2210149790.SGD","BK4167","IE00BGHQF748.EUR","IE00BN0W2W23.USD","IE00B64PRP62.GBP","SG9999014013.SGD","ACON","IE00BKPKM429.USD","IE00BN0W2T93.GBP","BK4588","LU2210150020.SGD","LU0314104364.USD","NDAQ","SG9999014039.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aclarion.com","stockEarnings":[{"period":"1week","weight":0.0158},{"period":"1month","weight":-0.1394},{"period":"3month","weight":0.2638},{"period":"6month","weight":-0.4705},{"period":"1year","weight":-0.5401},{"period":"ytd","weight":-0.3022}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.316115},{"month":2,"riseRate":0.25,"avgChangeRate":-0.352706},{"month":3,"riseRate":0.25,"avgChangeRate":-0.242097},{"month":4,"riseRate":0.25,"avgChangeRate":-0.127028},{"month":5,"riseRate":0.4,"avgChangeRate":0.029234},{"month":6,"riseRate":0.25,"avgChangeRate":-0.115199},{"month":7,"riseRate":0.5,"avgChangeRate":-0.021585},{"month":8,"riseRate":0.5,"avgChangeRate":-0.066272},{"month":9,"riseRate":0.25,"avgChangeRate":-0.18466},{"month":10,"riseRate":1,"avgChangeRate":0.110748},{"month":11,"riseRate":0,"avgChangeRate":-0.1724},{"month":12,"riseRate":0,"avgChangeRate":-0.242895}],"exchange":"NASDAQ","name":"ACLARION, INC","nameEN":"ACLARION, INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ACLARION, INC(ACON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ACLARION, INC(ACON) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ACLARION, INC,ACON,ACLARION, INC股票,ACLARION, INC股票老虎,ACLARION, INC股票老虎国际,ACLARION, INC行情,ACLARION, INC股票行情,ACLARION, INC股价,ACLARION, INC股市,ACLARION, INC股票价格,ACLARION, INC股票交易,ACLARION, INC股票购买,ACLARION, INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ACLARION, INC(ACON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ACLARION, INC(ACON) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction